Figure S3.

Nasal and Sinus Mucosa, Related to Figures 4 and 5

(A). Expression of ACE2 and TMPRSS2 across donors.

(B). Enhanced capture of ACE2 mRNA with second strand synthesis protocol employed in Seq-Well S³. Dot size represents fraction of cells expressing.

(C). Cultured human primary basal epithelial cells at confluence were treated with increasing doses (0.1 to 10ng/mL) of IFNα2, IFNγ, IL-4, IL-13, IL-17A, and IL-1B for 12 h and bulk RNA-seq analysis was performed (Replicate experiment using Human Donor 1 as in Figure 5)

(D). ACE2 expression by stimulation condition. Wilcoxon test between each cytokine (combined doses) versus rest: IFNα Bonferroni-adjusted p = 4.1E-07; IFNγ Bonferroni-adjusted p = 9.3E-03; all else n.s. ^∗∗∗ p < 0.001.

(E). ACE2 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001, ^∗ p < 0.05.

(F). ACE2 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001, ^∗ p < 0.05.

(G). IFITM1 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001.

(H). IFITM1 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001.

(I). GBP5 expression among cultured human primary basal epithelial cells. Wilcoxon test: IFNα versus IFNγ Bonferroni-adjusted p = 2.94E-07; IFNγ Bonferroni-adjusted p = 9.3E-03. TP10K: transcripts per 10,000 reads. ^∗∗∗ p < 0.001.

(J). GBP5 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001.

(K). GBP5 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: ^∗∗∗ p < 0.001.